Pancreatic ductal adenocarcinoma
Conditions
Interventions
Observation group:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Pathologically diagnosed pancreatic ductal adenocarcinoma; 2.Age =18 years; male or female; 3.Patients who have decided to receive treatment based on irinotecan hydrochloride liposome injection II; 4.The subjects voluntarily participated in this study and signed the informed consent form; 5.Women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until at least 6 months after the last dose of the study drug; furthermore, they must not be breastfeeding; 6.Male subjects with partners of childbearing potential must agree to avoid unprotected sexual intercourse or to use highly effective contraceptive measures from the time of signing the informed consent form until at least 3 months after the last dose of the study drug;
Exclusion criteria
Exclusion criteria: 1.Women with confirmed pregnancy or who are breastfeeding; 2.Other conditions deemed unsuitable for study inclusion by the researchers;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment efficacy; | — |
Countries
China
Contacts
Public ContactBaiyong Shen
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed